Journal of Peking University(Health Sciences) ›› 2016, Vol. 48 ›› Issue (3): 523-528. doi: 10.3969/j.issn.1671-167X.2016.03.025

• Article • Previous Articles     Next Articles

Study on the reliability of CardioChek PA for measuring lipid profile

GAO Ying, ZHU Cheng-gang, WU Na-qiong, GUO Yuan-lin, LIU Geng, DONG Qian, LI Jian-jun△   

  1. (Department of Dyslipidemia and Cardiovascular Disease, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China)
  • Online:2016-06-18 Published:2016-06-18
  • Contact: LI Jian-jun E-mail:lijianjun938@126.com
  • Supported by:

    Supported by the Capital Foundation for Medical Research and Development (2011400302)

Abstract:

Objective:To evaluate the clinical correlation between the CardioChek PA analyzer (CCPA) and a clinical laboratory reference method to use for screening program purposes. Methods: Fasting blood samples were collected on 325 patients (age: 23-86 years). One venous sample was collected using a serum tube for the evaluation on a Beckman reference analyzer. A second venous sample was collected in a lithium heparin tube and was evaluated on the CCPA analyzer. Linear regression analyses and Bland-Altman method were performed for each measured analyte: total cholesterol (TC), high density lipoproteincholesterol (HDL-C), triglycerides (TG) and low density lipoprotein-cholesterol (LDL-C). Results: Our results demonstrated a good clinical agreement for TC, HDL-C, TG and LDL-C(97.0%, 92.9%, 92.4% and 83.7%)in comparison with the CCPA to the reference analyzer. The correlation coefficients were 0.875, 0.813, 0.910, 0.864, respectively. P values all < 0.001. There was no significant difference in the detection rate of hyperlipidemia in TC, HDL-C and LDL-C. Conclusion: We have identified the pre-analytic phase as an important step to guarantee the quality of results and indicated that the CCPA is a reliable lipid point-of-care testing system that can be used for the application of clinical screening anywhere.

Key words:  Dyslipidemias, Point-of-care testing, Cardiovascular diseases

CLC Number: 

  • R589.2
[1] Tianjing ZHOU,Qiuping LIU,Minglu ZHANG,Xiaofei LIU,Jiali KANG,Peng SHEN,Hongbo LIN,Xun TANG,Pei GAO. Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 441-447.
[2] Ming-lu ZHANG,Qiu-ping LIU,Chao GONG,Jia-min WANG,Tian-jing ZHOU,Xiao-fei LIU,Peng SHEN,Hong-bo LIN,Xun TANG,Pei GAO. Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 480-487.
[3] Jia-min WANG,Qiu-ping LIU,Ming-lu ZHANG,Chao GONG,Shu-dan LIU,Wei-ye CHEN,Peng SHEN,Hong-bo LIN,Pei GAO,Xun TANG. Effectiveness of different screening strategies for type 2 diabete on preventing cardiovascular diseases in a community-based Chinese population using a decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 450-457.
[4] Chao GONG,Qiu-ping LIU,Jia-min WANG,Xiao-fei LIU,Ming-lu ZHANG,Han YANG,Peng SHEN,Hong-bo LIN,Xun TANG,Pei GAO. Effectiveness of statin treatment strategies for primary prevention of cardiovascular diseases in a community-based Chinese population: A decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 443-449.
[5] LIU Qiu-ping,CHEN Xi-jin,WANG Jia-min,LIU Xiao-fei,SI Ya-qin,LIANG Jing-yuan,SHEN Peng,LIN Hong-bo,TANG Xun,GAO Pei. Effectiveness of different screening strategies for cardiovascular diseases prevention in a community-based Chinese population: A decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 460-466.
[6] GUO Zi-ning, LIANG Zhi-sheng, ZHOU Yi, ZHANG Na, HUANG Jie. Genetic study of cardiovascular disease subtypes defined by International Classification of Diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 453-459.
[7] Jia-li CHEN,Yue-bo JIN,Yi-fan WANG,Xiao-ying ZHANG,Jing LI,Hai-hong YAO,Jing HE,Chun LI. Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1040-1047.
[8] YANG Chao, WANG Jin-wei, YANG Yao-zheng, BAI Kun-hao, GAO Bi-xia, ZHAO Ming-hui, ZHANG Lu-xia, WU Shou-ling, WANG Fang. Impact of anemia and chronic kidney disease on the risk of cardiovascular disease and all-cause mortality among diabetic patients [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 495-500.
[9] SI Ya-qin, TANG Xun, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, LIU Jian-jiang, GAO Pei, HU Yong-hua. Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 443-449.
[10] TANG Xun1, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, HUANG Shao-ping, DOU Hui-dong, GAO Pei, HU Yong-hua. Application of the China-PAR risk prediction model for atherosclerotic cardiovascular disease in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 439-445.
[11] YU Yang, SHENG Qin-Hui, ZHANG Bao-Wei, DING Wen-Hui. Left atrial size predicts adverse cardiac events in patients with non-obstruction hypertrophic cardiomyopathy [J]. Journal of Peking University(Health Sciences), 2014, 46(2): 207-210.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!